Castle Biosciences Inc
NASDAQ:CSTL
Castle Biosciences Inc
NASDAQ:CSTL
Price:
27.91
USD
-0.92%
Market Closed
Market Cap:
$814.7m
Balance Sheet
Balance Sheet Decomposition
Castle Biosciences Inc
Castle Biosciences Inc
Balance Sheet Decomposition is not available for
Castle Biosciences Inc
Castle Biosciences Inc
Balance Sheet
Castle Biosciences Inc
Castle Biosciences Inc
Currency: USD
| Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Cash & Cash Equivalents |
1
|
5
|
99
|
410
|
330
|
123
|
99
|
120
|
117
|
|
| Cash Equivalents |
1
|
5
|
99
|
410
|
330
|
123
|
99
|
120
|
117
|
|
| Short-Term Investments |
0
|
0
|
0
|
0
|
0
|
136
|
144
|
173
|
183
|
|
| Total Receivables |
5
|
12
|
15
|
13
|
17
|
24
|
38
|
51
|
43
|
|
| Accounts Receivables |
5
|
12
|
15
|
13
|
17
|
24
|
38
|
51
|
43
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Inventory |
0
|
1
|
1
|
2
|
2
|
4
|
8
|
8
|
10
|
|
| Other Current Assets |
1
|
1
|
2
|
5
|
5
|
6
|
6
|
8
|
8
|
|
| Total Current Assets |
7
|
18
|
117
|
430
|
354
|
292
|
296
|
360
|
361
|
|
| PP&E Net |
2
|
2
|
2
|
7
|
17
|
27
|
38
|
63
|
112
|
|
| PP&E Gross |
2
|
2
|
2
|
7
|
17
|
27
|
38
|
63
|
112
|
|
| Accumulated Depreciation |
1
|
1
|
1
|
2
|
3
|
8
|
8
|
13
|
18
|
|
| Intangible Assets |
0
|
0
|
0
|
0
|
89
|
116
|
107
|
96
|
89
|
|
| Goodwill |
0
|
0
|
0
|
0
|
0
|
11
|
11
|
11
|
11
|
|
| Note Receivable |
2
|
3
|
1
|
1
|
1
|
1
|
1
|
1
|
2
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
2
|
2
|
1
|
1
|
1
|
4
|
|
| Other Assets |
0
|
0
|
0
|
0
|
0
|
11
|
11
|
11
|
11
|
|
| Total Assets |
10
N/A
|
22
+129%
|
120
+434%
|
439
+267%
|
463
+5%
|
447
-3%
|
453
+1%
|
531
+17%
|
579
+9%
|
|
| Liabilities | ||||||||||
| Accounts Payable |
1
|
2
|
2
|
2
|
3
|
5
|
10
|
7
|
19
|
|
| Accrued Liabilities |
3
|
5
|
8
|
12
|
21
|
29
|
34
|
38
|
46
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
1
|
0
|
6
|
0
|
0
|
0
|
0
|
0
|
1
|
|
| Other Current Liabilities |
0
|
0
|
0
|
7
|
2
|
2
|
3
|
4
|
4
|
|
| Total Current Liabilities |
5
|
7
|
15
|
21
|
25
|
36
|
48
|
49
|
69
|
|
| Long-Term Debt |
18
|
25
|
19
|
0
|
0
|
0
|
0
|
10
|
10
|
|
| Deferred Income Tax |
0
|
0
|
0
|
0
|
1
|
0
|
0
|
2
|
2
|
|
| Other Liabilities |
1
|
1
|
0
|
3
|
25
|
12
|
14
|
14
|
27
|
|
| Total Liabilities |
24
N/A
|
33
+35%
|
35
+6%
|
24
-32%
|
51
+115%
|
48
-5%
|
62
+29%
|
75
+21%
|
108
+43%
|
|
| Equity | ||||||||||
| Common Stock |
36
|
47
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
51
|
58
|
52
|
63
|
94
|
161
|
218
|
200
|
224
|
|
| Additional Paid In Capital |
1
|
1
|
137
|
478
|
506
|
560
|
609
|
656
|
695
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
14
N/A
|
10
+29%
|
85
N/A
|
416
+388%
|
412
-1%
|
399
-3%
|
391
-2%
|
456
+17%
|
471
+3%
|
|
| Total Liabilities & Equity |
10
N/A
|
22
+129%
|
120
+434%
|
439
+267%
|
463
+5%
|
447
-3%
|
453
+1%
|
531
+17%
|
579
+9%
|
|
| Shares Outstanding | ||||||||||
| Common Shares Outstanding |
16
|
16
|
17
|
25
|
25
|
27
|
27
|
28
|
30
|
|
Switch to:
Switch to:
See Also
Discover More
